

Jessica A Palmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1136141/publications.pdf>

Version: 2024-02-01

13
papers

555
citations

1040056

9
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

900
citing authors

#	ARTICLE	IF	CITATIONS
1	Toward Good Read-Across Practice (GRAP) guidance. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 149-166.	1.5	134
2	Metabolomics as a Tool for Discovery of Biomarkers of Autism Spectrum Disorder in the Blood Plasma of Children. PLoS ONE, 2014, 9, e112445.	2.5	131
3	Supporting read-across using biological data. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 167-182.	1.5	78
4	Establishment and Assessment of a New Human Embryonic Stem Cell-Based Biomarker Assay for Developmental Toxicity Screening. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2013, 98, 343-363.	1.4	75
5	Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity. Toxicological Sciences, 2020, 174, 189-209.	3.1	34
6	A human induced pluripotent stem cell-based in vitro assay predicts developmental toxicity through a retinoic acid receptor-mediated pathway for a series of related retinoid analogues. Reproductive Toxicology, 2017, 73, 350-361.	2.9	29
7	A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential. Toxicological Sciences, 2020, 174, 218-240.	3.1	23
8	Metabolic Biomarkers of Prenatal Alcohol Exposure in Human Embryonic Stem Cell-Derived Neural Lineages. Alcoholism: Clinical and Experimental Research, 2012, 36, 1314-1324.	2.4	21
9	microRNAs signatures as potential biomarkers of structural cardiotoxicity in human-induced pluripotent stem-cell derived cardiomyocytes. Archives of Toxicology, 2022, 96, 2033-2047.	4.2	11
10	The use of human induced pluripotent stem cells to screen for developmental toxicity potential indicates reduced potential for non-combusted products, when compared to cigarettes. Current Research in Toxicology, 2020, 1, 161-173.	2.7	10
11	Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Predict the Cardiotoxicity Potential of Next Generation Nicotine Products. Frontiers in Toxicology, 2022, 4, 747508.	3.1	4
12	Quantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues. Birth Defects Research, 2022, 114, 1037-1055.	1.5	4
13	Corrigendum to: "Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity"; Toxicological Sciences, 2020, 177, 301-301.	3.1	1